Developer docs
API playgroundTry for free, no card

Search company profiles

Scailyte

Full company profile

uuid0000wd7

Namestring
Scailyte
Legal namestring
Scailyte AG
Websiteurl
scailyte.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Scailyte AG is a Basel-based precision medicine company that operates the ScaiVision™ analytics platform, which applies proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models to large-scale single-cell and spatial omics datasets matched with longitudinal clinical outcomes. The platform's core output is the identification of disease-driving cellular states and high-resolution patient endotypes that translate into predictive biomarkers, responder signatures, and Companion Diagnostics (CDx) candidates. Its flagship commercial program is the IBD Flagship, anchored by an exclusive data partnership with the Swiss IBD Cohort (4,000+ patients, 15+ years of longitudinal data, 40,000+ samples) — the largest tissue single-cell omics IBD Atlas the company has publicly described.

The company is organized around three partnership offerings for pharmaceutical and biotech clients: (1) asset de-risking and trial stratification via in silico validation using the IBD Foundation Model, (2) target discovery and combination positioning using deep spatial-omics, and (3) co-development of predictive biomarkers as Companion Diagnostics. Additional internal validation projects — including an NK Cell Therapy manufacturing QC marker and a CTCL blood-based diagnostic achieving 97 percent accuracy — demonstrate platform breadth beyond IBD. The company holds a pending diagnostic patent (EP19219889) and has executed its first named commercialization partnership (Hera Biotech) for an endometrial tissue-based diagnostic.

Commercially, Scailyte generates revenue through negotiated B2B enterprise partnerships with pharmaceutical companies, structured as licensing/royalty arrangements for pharma agreements and professional services / milestone-based payments for Companion Diagnostics co-development. Pricing is quote-based and not publicly disclosed. The company is privately held and venture-backed, having raised approximately CHF 6 million in Series A funding in September 2022 (Mirabaud, Swisscom Ventures) plus a follow-on round in December 2023, on top of earlier rounds led by Swisscom Ventures, Hemex, 4FOX Ventures, Verve Ventures, MassChallenge, Innos Suisse, and Venture Kick since 2017.

Short descriptiontext

Scailyte AG is a Basel-based precision medicine company whose ScaiVision™ platform applies proprietary AI to single-cell and spatial omics data, generating patient endotypes, biomarkers, and companion diagnostics for pharmaceutical partners in autoimmune disease (notably IBD) and immuno-oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell omics, precision medicine AI, biomarker discovery, patient endotyping, autoimmune disease research
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Medicine AI Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharma Partnership Agreements
TypeLicensing Royalties
Description

Scailyte generates revenue through strategic partnerships with pharmaceutical companies, offering services including asset de-risking, trial stratification, target discovery, and precision diagnostics co-development. Revenue is likely generated through milestone-based payments, licensing fees, and potentially royalty arrangements on successfully commercialized diagnostics.

scailyte.com
2Companion Diagnostics (CDx) Development
TypeProfessional Services
Description

Co-development of predictive biomarkers as Companion Diagnostics with pharma partners, potentially generating revenue through development fees, regulatory milestones, and commercialization royalties.

scailyte.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1ScaiVision
Description

Proprietary AI-powered analytics platform using Supervised Representation Learning for biomarker discovery and patient endotyping from single-cell and spatial omics data.

scailyte.com
Core offering1 text field

Scailyte develops and operates ScaiVision, an AI-powered analytics platform that combines large-scale single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states. The platform supports pharma partnerships across asset de-risking, trial stratification, target discovery, and co-development of companion diagnostics, with a primary focus on autoimmune diseases such as Inflammatory Bowel Disease (IBD).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >90% specificity achieved with first-in-kind tissue-based molecular diagnostic
+3 more records
Product overview1 text field

Scailyte is a precision medicine company offering ScaiVision™, an AI-powered analytics platform built on proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models. The platform processes large-scale single-cell and spatial omics data combined with longitudinal clinical outcomes to identify disease-driving cellular states and enable patient endotyping. The IBD Flagship Program represents the company's disease-specific application of this technology for Inflammatory Bowel Disease, while additional internal projects demonstrate capabilities in tissue-based and blood-based diagnostics for pharmaceutical and diagnostic partnerships.

Product and service3 records
1ScaiVision
CategoryAI-driven single-cell analytics platform
Description

AI-powered analytics platform that integrates multimodal single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states and generate predictive, translatable models for diagnostics and therapeutics. It is offered to pharmaceutical partners for asset de-risking, trial stratification, target discovery, and companion diagnostic co-development in autoimmune and immuno-oncology indications.

2IBD Flagship Program
CategoryPrecision medicine program (autoimmune disease)
Description

Strategic disease-focused application of the ScaiVision platform targeting Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease), offering pharma partners in silico validation, high-resolution patient endotyping, responder signature identification, and biomarker assay development for clinical trial design and precision therapeutics.

3Companion Diagnostics (CDx) Co-Development
CategoryCompanion diagnostics development services
Description

Service offering for pharmaceutical partners to co-develop predictive biomarker assays as Companion Diagnostics, translating ScaiVision-derived molecular signatures into clinically validated tests that ensure high response rates and clinical differentiation for partnered therapeutics.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Strategic partnership for global commercialization of Scailyte's first-in-kind tissue-based molecular diagnostic. Scailyte discovered unique molecular signatures in endometrial tissue that correlate with active lesions, achieving >90% specificity, and partnered this asset to Hera Biotech for worldwide commercialization.

2Swiss IBD Cohort
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive clinical data partnership providing access to 4,000+ IBD patients with 15+ years of longitudinal data and 40,000+ samples. This partnership anchors Scailyte's IBD Flagship Program and provides the foundational data for training AI models and disease modeling.

scailyte.com
3Key Opinion Leaders (KOLs) Network
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Network of leading key opinion leaders providing clinical samples and data from longitudinal national cohorts in IBD and other autoimmune diseases. Supports the company's discovery platform and AI model validation.

scailyte.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CytoReason is an AI platform that builds cell-level models of the immune system for pharma R&D, including patient stratification and target discovery in autoimmune and inflammatory disease. Closest direct peer to Scailyte given the overlap in single-cell/immune modeling, pharma partnership GTM, and disease focus on IBD and immunology.

TypeDirect peer
Description

Owkin applies AI to multi-modal patient data to support pharma with target discovery, trial optimization, and companion diagnostics across oncology and immunology. Comparable enterprise sales motion, multi-modal foundation model approach, and pharma partnership revenue model.

TypeDirect peer
Description

Insitro combines machine learning with high-throughput biology to discover and develop therapeutics, with a partnership model with pharma. Similar AI-first platform positioning for drug discovery, though Insitro is more development-stage and vertically integrated into therapeutics.

TypeDirect peer
Description

GNS applies causal AI to multi-modal patient data to support pharma with patient stratification, trial enrichment, and biomarker discovery. Comparable in the precision-medicine AI-for-pharma value proposition and partnership-driven GTM.

5Tempus Labs
TypeBroad incumbent
Description

Tempus is a large precision medicine data and AI platform that partners with pharma on biomarker discovery, CDx, and real-world evidence. Significantly larger scale and broader data library (multiomics plus clinical), serving as a broad incumbent in the same enterprise pharma AI category.

TypeBroad incumbent
Description

Recursion combines high-throughput biology with foundation models and AI to discover therapeutics at scale. Overlaps in AI-driven pharma R&D and foundation model narrative, but operates at a much larger scale and is more therapeutics-focused rather than a partnership/CDx platform.

TypeDirect peer
Description

Adaptive uses immune repertoire sequencing and single-cell immune profiling to develop diagnostics and partner with pharma on antigen discovery and immune monitoring. Direct overlap with Scailyte's single-cell immune profiling approach and pharma CDx partnership motion.

TypeBroad incumbent
Description

Benevolent AI applies foundation models to biomedical knowledge graphs to identify novel targets and support pharma R&D decisions. Comparable in AI-for-pharma R&D positioning and partnership-led model, though more knowledge-graph-based than single-cell-omics-based.

TypeBroad incumbent
Description

Schrödinger provides computational chemistry and biology software plus a partnered therapeutics pipeline, working with pharma on target identification and lead optimization. Broad incumbent in AI/computation-enabled pharma R&D with a software-plus-partnerships model.

TypeOthers
Description

10x Genomics is the dominant provider of single-cell and spatial omics instrumentation and software used by pharma and academic labs. Ecosystem/supplier relationship to Scailyte, which depends on 10x platforms (or similar) for generating the single-cell data that feeds ScaiVision.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scailyte

Precision Medicine AI Softwarescailyte.com

Scailyte AG is a Basel-based precision medicine company whose ScaiVision™ platform applies proprietary AI to single-cell and spatial omics data, generating patient endotypes, biomarkers, and companion diagnostics for pharmaceutical partners in autoimmune disease (notably IBD) and immuno-oncology.

What Scailyte does

Scailyte AG is a Basel-based precision medicine company that operates the ScaiVision™ analytics platform, which applies proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models to large-scale single-cell and spatial omics datasets matched with longitudinal clinical outcomes. The platform's core output is the identification of disease-driving cellular states and high-resolution patient endotypes that translate into predictive biomarkers, responder signatures, and Companion Diagnostics (CDx) candidates. Its flagship commercial program is the IBD Flagship, anchored by an exclusive data partnership with the Swiss IBD Cohort (4,000+ patients, 15+ years of longitudinal data, 40,000+ samples) — the largest tissue single-cell omics IBD Atlas the company has publicly described.

The company is organized around three partnership offerings for pharmaceutical and biotech clients: (1) asset de-risking and trial stratification via in silico validation using the IBD Foundation Model, (2) target discovery and combination positioning using deep spatial-omics, and (3) co-development of predictive biomarkers as Companion Diagnostics. Additional internal validation projects — including an NK Cell Therapy manufacturing QC marker and a CTCL blood-based diagnostic achieving 97 percent accuracy — demonstrate platform breadth beyond IBD. The company holds a pending diagnostic patent (EP19219889) and has executed its first named commercialization partnership (Hera Biotech) for an endometrial tissue-based diagnostic.

Commercially, Scailyte generates revenue through negotiated B2B enterprise partnerships with pharmaceutical companies, structured as licensing/royalty arrangements for pharma agreements and professional services / milestone-based payments for Companion Diagnostics co-development. Pricing is quote-based and not publicly disclosed. The company is privately held and venture-backed, having raised approximately CHF 6 million in Series A funding in September 2022 (Mirabaud, Swisscom Ventures) plus a follow-on round in December 2023, on top of earlier rounds led by Swisscom Ventures, Hemex, 4FOX Ventures, Verve Ventures, MassChallenge, Innos Suisse, and Venture Kick since 2017.

Scailyte firmographics

Firmographics
Name
Scailyte
Legal name
Scailyte AG
Website
https://scailyte.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Scailyte AG is a Basel-based precision medicine company whose ScaiVision™ platform applies proprietary AI to single-cell and spatial omics data, generating patient endotypes, biomarkers, and companion diagnostics for pharmaceutical partners in autoimmune disease (notably IBD) and immuno-oncology.
Ownership category
akta.pro rank

Scailyte industry classification

Industry
Product category
Precision Medicine AI Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Single-cell omics
  • Precision medicine AI
  • Biomarker discovery
  • Patient endotyping
  • Autoimmune disease research

Where Scailyte is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Scailyte business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharma Partnership Agreements: Scailyte generates revenue through strategic partnerships with pharmaceutical companies, offering services including asset de-risking, trial stratification, target discovery, and precision diagnostics co-development. Revenue is likely generated through milestone-based payments, licensing fees, and potentially royalty arrangements on successfully commercialized diagnostics.
  2. Companion Diagnostics (CDx) Development: Co-development of predictive biomarkers as Companion Diagnostics with pharma partners, potentially generating revenue through development fees, regulatory milestones, and commercialization royalties.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Scailyte product offering

Product offering

Core offering

Scailyte develops and operates ScaiVision, an AI-powered analytics platform that combines large-scale single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states. The platform supports pharma partnerships across asset de-risking, trial stratification, target discovery, and co-development of companion diagnostics, with a primary focus on autoimmune diseases such as Inflammatory Bowel Disease (IBD).

Product overview

Scailyte is a precision medicine company offering ScaiVision™, an AI-powered analytics platform built on proprietary Supervised Representation Learning and Deep Generative/Single-Cell Foundation Models. The platform processes large-scale single-cell and spatial omics data combined with longitudinal clinical outcomes to identify disease-driving cellular states and enable patient endotyping. The IBD Flagship Program represents the company's disease-specific application of this technology for Inflammatory Bowel Disease, while additional internal projects demonstrate capabilities in tissue-based and blood-based diagnostics for pharmaceutical and diagnostic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • ScaiVision: Proprietary AI-powered analytics platform using Supervised Representation Learning for biomarker discovery and patient endotyping from single-cell and spatial omics data.

Products and services

  • ScaiVision AI-powered analytics platform that integrates multimodal single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states and generate predictive, translatable models for diagnostics and therapeutics. It is offered to pharmaceutical partners for asset de-risking, trial stratification, target discovery, and companion diagnostic co-development in autoimmune and immuno-oncology indications.
  • IBD Flagship Program Strategic disease-focused application of the ScaiVision platform targeting Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease), offering pharma partners in silico validation, high-resolution patient endotyping, responder signature identification, and biomarker assay development for clinical trial design and precision therapeutics.
  • Companion Diagnostics (CDx) Co-Development Service offering for pharmaceutical partners to co-develop predictive biomarker assays as Companion Diagnostics, translating ScaiVision-derived molecular signatures into clinically validated tests that ensure high response rates and clinical differentiation for partnered therapeutics.

Quantifiable outcome

  • >90% specificity achieved with first-in-kind tissue-based molecular diagnostic
  • +3 more outcomes

Companies that use Scailyte

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Scailyte technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Scailyte partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Hera BiotechcoreOEM/ Whitelabel/ Licensing PartnerStrategic partnership for global commercialization of Scailyte's first-in-kind tissue-based molecular diagnostic. Scailyte discovered unique molecular signatures in endometrial tissue that correlate with active lesions, achieving >90% specificity, and partnered this asset to Hera Biotech for worldwide commercialization.
  • Swiss IBD CohortcoreStrategic or Co-development PartnerExclusive clinical data partnership providing access to 4,000+ IBD patients with 15+ years of longitudinal data and 40,000+ samples. This partnership anchors Scailyte's IBD Flagship Program and provides the foundational data for training AI models and disease modeling.
  • Key Opinion Leaders (KOLs) NetworkcoreStrategic or Co-development PartnerNetwork of leading key opinion leaders providing clinical samples and data from longitudinal national cohorts in IBD and other autoimmune diseases. Supports the company's discovery platform and AI model validation.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Scailyte competitors and assessment

Company assessment

Direct peers

  • CytoReason: CytoReason is an AI platform that builds cell-level models of the immune system for pharma R&D, including patient stratification and target discovery in autoimmune and inflammatory disease. Closest direct peer to Scailyte given the overlap in single-cell/immune modeling, pharma partnership GTM, and disease focus on IBD and immunology.
  • Owkin: Owkin applies AI to multi-modal patient data to support pharma with target discovery, trial optimization, and companion diagnostics across oncology and immunology. Comparable enterprise sales motion, multi-modal foundation model approach, and pharma partnership revenue model.
  • Insitro: Insitro combines machine learning with high-throughput biology to discover and develop therapeutics, with a partnership model with pharma. Similar AI-first platform positioning for drug discovery, though Insitro is more development-stage and vertically integrated into therapeutics.
  • GNS (GNS Healthcare): GNS applies causal AI to multi-modal patient data to support pharma with patient stratification, trial enrichment, and biomarker discovery. Comparable in the precision-medicine AI-for-pharma value proposition and partnership-driven GTM.
  • Adaptive Biotechnologies: Adaptive uses immune repertoire sequencing and single-cell immune profiling to develop diagnostics and partner with pharma on antigen discovery and immune monitoring. Direct overlap with Scailyte's single-cell immune profiling approach and pharma CDx partnership motion.

Broad incumbents

  • Tempus Labs: Tempus is a large precision medicine data and AI platform that partners with pharma on biomarker discovery, CDx, and real-world evidence. Significantly larger scale and broader data library (multiomics plus clinical), serving as a broad incumbent in the same enterprise pharma AI category.
  • Recursion Pharmaceuticals: Recursion combines high-throughput biology with foundation models and AI to discover therapeutics at scale. Overlaps in AI-driven pharma R&D and foundation model narrative, but operates at a much larger scale and is more therapeutics-focused rather than a partnership/CDx platform.
  • Benevolent AI: Benevolent AI applies foundation models to biomedical knowledge graphs to identify novel targets and support pharma R&D decisions. Comparable in AI-for-pharma R&D positioning and partnership-led model, though more knowledge-graph-based than single-cell-omics-based.
  • Schrödinger: Schrödinger provides computational chemistry and biology software plus a partnered therapeutics pipeline, working with pharma on target identification and lead optimization. Broad incumbent in AI/computation-enabled pharma R&D with a software-plus-partnerships model.

Others

  • 10x Genomics: 10x Genomics is the dominant provider of single-cell and spatial omics instrumentation and software used by pharma and academic labs. Ecosystem/supplier relationship to Scailyte, which depends on 10x platforms (or similar) for generating the single-cell data that feeds ScaiVision.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Scailyte social profiles

Digital presence

Scailyte financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scailyte leadership team

Management profile

Number of profiles

Profiles4 records

Scailyte funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scailyte M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scailyte

What does Scailyte do?

Scailyte develops and operates ScaiVision, an AI-powered analytics platform that combines large-scale single-cell and spatial omics data with longitudinal clinical outcomes to identify disease-driving cellular states. The platform supports pharma partnerships across asset de-risking, trial stratification, target discovery, and co-development of companion diagnostics, with a primary focus on autoimmune diseases such as Inflammatory Bowel Disease (IBD).

Is Scailyte a public or private company?

Scailyte is a private company. It is classified as venture growth investor backed and is currently operating.

When was Scailyte founded?

Scailyte was founded in 2017. It employs 11 to 50 people.

Where is Scailyte based?

Scailyte is headquartered in Basel, Switzerland, in the Europe region.

How does Scailyte make money?

Two revenue lines are on record. Pharma Partnership Agreements are the primary driver. The others are companion Diagnostics (CDx) Development.

Who are Scailyte's main competitors?

Direct peers on record are CytoReason, Owkin, Insitro, GNS (GNS Healthcare) and Adaptive Biotechnologies. Broad incumbents are Tempus Labs, Recursion Pharmaceuticals, Benevolent AI and Schrödinger. 10x Genomics is listed as an others.

Does Scailyte have an API?

No public API is recorded for Scailyte.

What industry is Scailyte in?

Scailyte's product category is Precision Medicine AI Software. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54151 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comScailyte Strengthens Its LeadershipScailyte appointed Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Darrin Crisitello to its Board of Directors. The appointments aim to support commercial growth and expand North American presence. The company remains committed to advancing precision medicine with single-cell multi-omics and AI.Tech.euSwiss AI company Scailyte sells Endometriosis diagnostic assets to Hera BiotechSwiss AI company Scailyte agreed to sell its endometriosis diagnostic assets to US Hera Biotech. The deal, with undisclosed financials, consolidates the only two tissue-based endometriosis diagnostic programs. Hera plans to launch its first diagnostic product in the US fertility market in late 2024.YahooHera Biotech to Make First Acquisition in the Endometriosis Diagnostic Market and Enter Into Strategic Partnership With ScailyteHera Biotech agreed to acquire Scailyte's endometriosis diagnostic assets and IP, consolidating the two tissue-based diagnostic programs. The combined portfolio's first product will launch in the US fertility market in late 2024, with a second product for OB/GYN follow-up. The transaction is expected to close by end of January 2024.Business Wire BlogHera Biotech to Make First Acquisition in the Endometriosis Diagnostic Market and Enter Into Strategic Partnership With ScailyteHera Biotech agreed to acquire Scailyte's endometriosis diagnostic assets and IP, consolidating the two tissue-based diagnostic programs. The companies expect to close the deal by end of January 2024, with the first product launching in the US fertility market in late 2024. Hera also announced a $15M Series A raise.VenturelabScailyte bolsters Series A funding to USD 8 Million, accelerating the innovation in the immuno-oncology landscapeScailyte has extended its Series A funding to USD 8 million to accelerate innovation in the immuno-oncology landscape. The company plans to use the capital to expand its presence in the US market and seek partnerships with biotech and pharma firms.startupticker.chScailyte reaches USD 8 million in Series ABasel-based medtech startup Scailyte has raised USD 8 million in a Series A funding round to expand its U.S. partnerships and promote biomarker discovery. The company plans to use the capital to advance its AI-powered ScaiVision platform for precision medicine and strengthen its presence in the U.S. market.startupticker.chStartups welcome seasoned industry leaders to their boardFive startups have appointed seasoned industry leaders to their boards: Jan Lichtenberg to Scailyte, Santiago Arroyo to GlycoEra, Caroline Forster to Rubirosa, and Kathrin Wolff-Schmandt to Aktionariat. The appointments aim to leverage their experience and networks to drive growth.NewswireScailyte Announces Jan Lichtenberg, CEO at inSphero, as a Member of the Board of DirectorsScailyte appointed Jan Lichtenberg, CEO of inSphero, to its Board of Directors. Lichtenberg brings over 20 years of life sciences experience, including roles at Hocoma and Uwatec. He replaces Jean-Pierre Rosat, who will remain as a Board Observer.ZapierScailyte Closes Series A Funding With a CHF 6 Million Investment to Develop Strategic Partnerships in Immuno-OncologyScailyte AG secured CHF 6 million in Series A funding from a Swiss family office, Mirabaud bank, and existing investors including Swisscom Ventures. The company plans to advance its endometriosis biomarker into prototype validation in the United States and expand strategic partnerships in immuno-oncology and single-cell omics. This financing supports the development of its ScaiVision analytics platform to improve clinical trial success rates for novel cancer therapies.